Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study

• Glavni autori: Nizar Mahlaoui (Autor), Fanny Fouyssac (Autor), Françoise Mazingue (Autor), Coralie Mallebranche (Autor), Malika Barthez-Toullec (Autor), Lamia Denti (Autor), Kalaivani Ruhier (Autor), Marie-Hélène (Autor), Aude Marie-Cardine (Autor), Nathalie Aladjidi (Autor), Jean-Louis Stephan (Autor)
• Format: Knjiga
• Izdano: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

IntroductionThis study presents the results of a real-life, multicenter, prospective, post-approval safety evaluation of Clairyg® 50 mg/mL, a 5% intravenous immunoglobulin (IVIg) liquid, in 59 children (aged < 12 years) with primary immunodeficiency diseases (PID) (n = 32) or immune thrombocytope...